TY  - JOUR
AU  - Lozano, Rebeca
AU  - Lorente, David
AU  - Aragon, Isabel M
AU  - Romero-Laorden, Nuria
AU  - Nombela, Paz
AU  - Mateo, Joaquim
AU  - Reid, Alison H M
AU  - Cendón, Ylenia
AU  - Bianchini, Diletta
AU  - Llacer, Casilda
AU  - Sandhu, Shahneen K
AU  - Sharp, Adam
AU  - Rescigno, Pasquale
AU  - Garcés, Teresa
AU  - Pacheco, Maria I
AU  - Flohr, Penelope
AU  - Massard, Christophe
AU  - López-Casas, Pedro P
AU  - Castro, Elena
AU  - de Bono, Johann S
AU  - Olmos, David
PY  - 2021
DO  - 10.3390/cancers13102334
SN  - 2072-6694
UR  - https://hdl.handle.net/10668/25067
T2  - Cancers
AB  - Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis...
LA  - en
KW  - PSA
KW  - biomarkers
KW  - circulating tumor cells
KW  - docetaxel
KW  - metastatic castration-resistant prostate cancer
TI  - Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
TY  - research article
VL  - 13
ER  -